Scholarlink

Background <p>Diffuse large B-cell lymphoma (DLBCL) patients with 17p deletion (17p<sup>-</sup>) show variable outcomes under R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) therapy. <i>ALOX15B</i> (arachidonate 15-lipoxygenase type B), located on chromosome 17p, regulates immune responses via arachidonic acid (AA) metabolism. This study investigates its role in DLBCL progression and explores its epigenetic regulation and therapeutic potential.</p> Methods <p>We analyzed bulk and single-cell transcriptomic data from DLBCL cohorts to evaluate <i>ALOX15B</i> expression and its correlation with clinical outcomes, immune microenvironment, and therapy resistance. Functional assays using siRNA knockdown, luciferase reporter, and drug sensitivity experiments were performed in DLBCL cell lines. Murine and patient-derived xenograft (PDX) models were employed to assess tumor behavior and treatment efficacy in vivo. Chromatin immunoprecipitation sequencing (ChIP-seq), assay for transposase-accessible chromatin using sequencing (ATAC-seq), were conducted to explore the epigenetic regulation of <i>ALOX15B</i>.</p> Results <p>Low <i>ALOX15B</i> expression was associated with inferior progression-free survival (PFS), immunosuppressive microenvironment, and reduced CD8 <sup>+</sup> T cell cytotoxicity in DLBCL. Mechanistically, <i>ALOX15B</i> deficiency led to upregulation of COX-2/PGE2 signaling and downregulation of the TAP1/MHC-I antigen presentation axis. Silencing <i>ALOX15B</i> promoted tumor cell proliferation and resistance to doxorubicin. Epigenetically, HDAC1/2 were enriched at the <i>ALOX15B</i> promoter region, repressing its expression. Treatment with the HDAC inhibitor tucidinostat restored <i>ALOX15B</i> expression, enhanced tumor cell apoptosis, reinstated antigen presentation, and reprogrammed the tumor immune landscape in both cell lines and in vivo models.</p> Conclusions <p><i>ALOX15B</i> is a key epigenetically regulated gene in DLBCL that modulates the tumor immune microenvironment and response to chemotherapy. Its downregulation promotes immune evasion and treatment resistance, while tucidinostat effectively restores its expression and anti-tumor immunity. These findings highlight <i>ALOX15B</i> as a prognostic biomarker and therapeutic target, particularly in 17p<sup>−</sup> DLBCL.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Low expression of ALOX15B modulates immunosuppressive tumor microenvironment in diffuse large B-cell lymphoma via the TAP1/MHC-I axis

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年1月12日

查看全文
  • Li Wang,
  • Jiaying Liu,
  • Yucui Shang,
  • Lanxin Zhang,
  • Muchen Zhang,
  • Di Fu,
  • Shu Cheng,
  • Pengpeng Xu,
  • Eurydice Anegeli,
  • Guilhem Bousquet,
  • Ying Fang,
  • Yu Liu,
  • Wei-Li Zhao

摘要

Background

Diffuse large B-cell lymphoma (DLBCL) patients with 17p deletion (17p-) show variable outcomes under R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) therapy. ALOX15B (arachidonate 15-lipoxygenase type B), located on chromosome 17p, regulates immune responses via arachidonic acid (AA) metabolism. This study investigates its role in DLBCL progression and explores its epigenetic regulation and therapeutic potential.

Methods

We analyzed bulk and single-cell transcriptomic data from DLBCL cohorts to evaluate ALOX15B expression and its correlation with clinical outcomes, immune microenvironment, and therapy resistance. Functional assays using siRNA knockdown, luciferase reporter, and drug sensitivity experiments were performed in DLBCL cell lines. Murine and patient-derived xenograft (PDX) models were employed to assess tumor behavior and treatment efficacy in vivo. Chromatin immunoprecipitation sequencing (ChIP-seq), assay for transposase-accessible chromatin using sequencing (ATAC-seq), were conducted to explore the epigenetic regulation of ALOX15B.

Results

Low ALOX15B expression was associated with inferior progression-free survival (PFS), immunosuppressive microenvironment, and reduced CD8 + T cell cytotoxicity in DLBCL. Mechanistically, ALOX15B deficiency led to upregulation of COX-2/PGE2 signaling and downregulation of the TAP1/MHC-I antigen presentation axis. Silencing ALOX15B promoted tumor cell proliferation and resistance to doxorubicin. Epigenetically, HDAC1/2 were enriched at the ALOX15B promoter region, repressing its expression. Treatment with the HDAC inhibitor tucidinostat restored ALOX15B expression, enhanced tumor cell apoptosis, reinstated antigen presentation, and reprogrammed the tumor immune landscape in both cell lines and in vivo models.

Conclusions

ALOX15B is a key epigenetically regulated gene in DLBCL that modulates the tumor immune microenvironment and response to chemotherapy. Its downregulation promotes immune evasion and treatment resistance, while tucidinostat effectively restores its expression and anti-tumor immunity. These findings highlight ALOX15B as a prognostic biomarker and therapeutic target, particularly in 17p− DLBCL.